ATE431748T1 - Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren - Google Patents
Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäurenInfo
- Publication number
- ATE431748T1 ATE431748T1 AT01980694T AT01980694T ATE431748T1 AT E431748 T1 ATE431748 T1 AT E431748T1 AT 01980694 T AT01980694 T AT 01980694T AT 01980694 T AT01980694 T AT 01980694T AT E431748 T1 ATE431748 T1 AT E431748T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acids
- combination
- sugar
- administration
- formulations containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0026892A GB0026892D0 (en) | 2000-11-03 | 2000-11-03 | Nucleic acid delivery |
GB0110525A GB0110525D0 (en) | 2001-04-30 | 2001-04-30 | Nucleic acid delivery |
GB0112585A GB0112585D0 (en) | 2001-05-24 | 2001-05-24 | Nucleic acid delivery |
PCT/GB2001/004878 WO2002036167A1 (en) | 2000-11-03 | 2001-11-02 | Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE431748T1 true ATE431748T1 (de) | 2009-06-15 |
Family
ID=27255959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01980694T ATE431748T1 (de) | 2000-11-03 | 2001-11-02 | Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1330265B1 (de) |
JP (1) | JP4426757B2 (de) |
AT (1) | ATE431748T1 (de) |
AU (2) | AU2002212486B2 (de) |
CA (1) | CA2426334C (de) |
DE (1) | DE60138762D1 (de) |
ES (1) | ES2327491T3 (de) |
MX (1) | MXPA03003983A (de) |
NZ (1) | NZ525362A (de) |
WO (1) | WO2002036167A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
US8647826B2 (en) | 2001-03-14 | 2014-02-11 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer |
BRPI0515819A (pt) * | 2004-12-01 | 2008-08-05 | Genzyme Corp | métodos para o fornecimento direcionado de material genético ao fìgado |
EA034858B1 (ru) * | 2015-01-30 | 2020-03-30 | Фрезениус Каби Дойчланд Гмбх | Применение модифицированных полимеров глюкозы для снижения метастазирования опухолей |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3789880T2 (de) * | 1986-01-31 | 1994-09-08 | Beecham Group Plc | Isolierung und Expression von bei der Biosynthese von Beta-Laktamen beteiligten Genen. |
DE19748290B8 (de) * | 1997-10-31 | 2009-09-03 | Fresenius Medical Care Deutschland Gmbh | Lösung für die Peritonealdialyse |
AU779579B2 (en) * | 1999-08-10 | 2005-01-27 | Innovata Plc | Method for delivery of therapeutic agents using a solution of dextrin |
-
2001
- 2001-11-02 CA CA2426334A patent/CA2426334C/en not_active Expired - Fee Related
- 2001-11-02 JP JP2002538976A patent/JP4426757B2/ja not_active Expired - Fee Related
- 2001-11-02 AU AU2002212486A patent/AU2002212486B2/en not_active Ceased
- 2001-11-02 DE DE60138762T patent/DE60138762D1/de not_active Expired - Lifetime
- 2001-11-02 AT AT01980694T patent/ATE431748T1/de not_active IP Right Cessation
- 2001-11-02 MX MXPA03003983A patent/MXPA03003983A/es active IP Right Grant
- 2001-11-02 ES ES01980694T patent/ES2327491T3/es not_active Expired - Lifetime
- 2001-11-02 EP EP01980694A patent/EP1330265B1/de not_active Expired - Lifetime
- 2001-11-02 NZ NZ525362A patent/NZ525362A/en not_active IP Right Cessation
- 2001-11-02 AU AU1248602A patent/AU1248602A/xx active Pending
- 2001-11-02 WO PCT/GB2001/004878 patent/WO2002036167A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP4426757B2 (ja) | 2010-03-03 |
NZ525362A (en) | 2004-11-26 |
AU1248602A (en) | 2002-05-15 |
AU2002212486B2 (en) | 2007-10-04 |
WO2002036167A1 (en) | 2002-05-10 |
EP1330265B1 (de) | 2009-05-20 |
ES2327491T3 (es) | 2009-10-30 |
EP1330265A1 (de) | 2003-07-30 |
WO2002036167A8 (en) | 2002-09-26 |
CA2426334C (en) | 2011-09-20 |
JP2004512380A (ja) | 2004-04-22 |
CA2426334A1 (en) | 2002-05-10 |
MXPA03003983A (es) | 2003-08-19 |
DE60138762D1 (de) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9910251A (pt) | Estimulação hematopoiética | |
ATE237312T1 (de) | In liposomen verkapselte nukleinsäurekomplexe | |
ATE429210T1 (de) | Orale flüssige zusammensetzungen | |
DK0839026T3 (da) | Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler | |
MY135913A (en) | Fsh and fsh variant formulations comprising benzyl alcohol as a preservative | |
AU2001254624A1 (en) | Human coagulation factor vii variants | |
AU2002214596A1 (en) | Methods and compositions for nucleic acid delivery | |
EP1409506A4 (de) | Verfahren und zusammensetzungen zur rnai vermittelten inhibierung der genexpression in säugetieren | |
DE60038011D1 (de) | Verbesserung der immunantwort als anwendung in impfstoff und gentherapie | |
WO2004011060A3 (en) | Delivery of molecules and complexes to mammalian cells in vivo | |
DE60036537D1 (de) | Zusammensetzungen zur gentherapie von diabetes | |
ATE319848T1 (de) | Herstellung von polyketiden | |
MXPA05012319A (es) | Suministro de compuestos con celulas sanguineas rehidratadas. | |
WO2003054154A3 (en) | Antisense modulation of mucin 1, transmembrane expression | |
IL145557A0 (en) | Immunoabsorber for use in sepsis therapy | |
DK1123414T3 (da) | Antisense-modulering af integrin alpha 4.ekspression | |
BR0014519A (pt) | Sequências de sinais para a preparação de leu-herudin através da secreção por e. coli no meio de cultura | |
WO2003092612A3 (en) | VECTORS HAVING BOTH ISOFORMS OF β-HEXOSAMINIDASE | |
ATE431748T1 (de) | Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren | |
HK1063713A1 (en) | Enzyme treated maple syrup, shelf stable, pure maple based products, and blended products | |
IL134593A0 (en) | A cell system for in-vivo expression of an interferon beta protein, pharmaceutical compositions containing the same and methods for the preparation thereof | |
WO2003106640A3 (en) | CELL TARGETING METHODS AND COMPOSITIONS | |
CA2441535A1 (en) | Methods for delivering nucleic acid molecules into cells and assessment thereof | |
BR9913132A (pt) | Nucleotìdeos da antitrombina e proteìnas do moscão | |
EP1248635A4 (de) | Antisense-modulation der glykogen-synthase-kinase-3alpha-expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |